Cartesian Therapeutics, Inc. 8K

Cartesian Therapeutics reported Q2 2026 results, advanced multiple Descartes-08 clinical programs, entered a strategic in vivo CAR-T partnership with WestGene, and secured up to $150 million in non-dilutive financing from K2 HealthVentures, extending its cash runway into 2028.

On August 6, 2026, Cartesian Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026, highlighted progress across its Descartes-08 clinical programs, announced a strategic licensing partnership with WestGene BioPharma to develop an in vivo CAR-T platform for autoimmune diseases, and detailed a non-dilutive credit facility of up to $150 million from K2 HealthVentures that extends the Company’s cash runway into 2028. The Company’s Phase 3 AURORA trial in myasthenia gravis continues with top-line data expected in the first quarter of 2027 and a planned BLA filing in mid-2027, while the Phase 2 TRITON myositis trial and the Phase 1/2 HELIOS pediatric trial in JDM and other autoimmune diseases remain on track with data anticipated in the first half of 2027. Cartesian expects to initiate a Phase 1 in vivo MG trial using WestGene’s targeted lipid nanoparticle platform in the second half of 2026 with clinical data expected in the first half of 2027. Financially, the Company reported $149.3 million in cash, cash equivalents and restricted cash as of June 30, 2026, second-quarter research and development expenses of $20.4 million, general and administrative expenses of $8.7 million, and net income of $15.8 million primarily driven by a non-cash gain on the change in fair value of its contingent value rights liability, while continuing to carry a significant CVR liability and stockholders’ deficit on its balance sheet.

Filing Facts

CIK

1453687

Ticker

-

Form

8K

Source Type

sec

Accession

0001453687-26-000100

Alert Tier

7